Vanda Pharmaceuticals Inc. (VNDA) Financial Analysis & Valuation | Quarter Chart
Vanda Pharmaceuticals Inc. (VNDA)
VNDAPrice: $7.32
Fair Value: 🔒
🔒score
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the trea... more
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercializ... more
Description
Shares
| Market Cap | $432.67M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Mihael H. Polymeropoulos |
| IPO Date | 2006-04-12 | CAGR | 0.54% |
| Employees | 368 | Website | www.vandapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
VNDA chart loading...
Fundamentals
Technicals
| Enterprise Value | $592.25M | P/E Ratio | -1.96 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 11787.48 | P/B Ratio | 5562.27 |
| P/CF Ratio | -31340.93 | P/FCF Ratio | -31049.74 |
| EPS | $-3.74 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 11.12% | Gross Margin | 0.68% |
| Operating Margin | -0.72% | Profit Margin | -1.02% |
| ROE | -0.44% | ROA | -0.37% |
| ROCE | -0.32% | Current Ratio | 3.12 |
| Quick Ratio | 3.1 | Cash Ratio | 0.59 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 1.77 | Piotroski Score | 1 |